Mingzhu Yan

Dr. Mingzhu Yan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2018 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
MYMingzhu Yan
Mingzhu Yan
LYLinhu Ye
Linhu Ye
SYShutao Yin
Shutao Yin
XLXiaotong Lu
Xiaotong Lu
XLXiaoyi Liu
Xiaoyi Liu
HHHongbo Hu
Hongbo Hu

1 March 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YLYong-Guang Liu
Yong-Guang Liu
SJSu-Wei Jin
Su-Wei Jin
SZShan-Shan Zhang
Shan-Shan Zhang
TXTian-Ji Xia
Tian-Ji Xia
YLYong-Hong Liao
Yong-Hong Liao
QCQi Chang
Qi Chang
Type III interferon (IFN-λ), a new member of the IFN family, was initially considered to possess antiviral functions similar to those of type I interferon, both of which are induced via the JAK/STAT pathway. Nevertheless, recent findings demonstrated that IFN-λ exerts a nonredundant antiviral function at the mucosal surface, preferentially produced in epithelial cells in contrast to type I interferon, and its function cannot be replaced by type I interferon. This review summarizes recent studies showing that IFN-λ inhibits the spread of viruses from the cell surface to the body. Further studies have found that the role of IFN-λ is not only limited to the abovementioned functions, but it can also can exert direct and/or indirect effects on immune cells in virus-induced inflammation. This review focuses on the antiviral activity of IFN-λ in the mucosal epithelial cells and its action on immune cells and summarizes the pathways by which IFN-λ exerts its action and differentiates it from other interferons in terms of mechanism. Finally, we conclude that IFN-λ is a potent epidermal antiviral factor that enhances the respiratory mucosal immune response and has excellent therapeutic potential in combating respiratory viral infections.

1 February 2024 in Journal of Advanced Research
Verified
Journal Article
Open access
SJSuwei Jin
Suwei Jin
YLYujia Li
Yujia Li
TXTianji Xia
Tianji Xia
YLYongguang Liu
Yongguang Liu
SZShanshan Zhang
Shanshan Zhang
MYMingzhu Yan
Mingzhu Yan
Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, whereas there is no approved drug therapy due to its complexity. Studies are emerging to discuss the role of selective autophagy in the pathogenesis of NAFLD, because the specificity among the features of selective autophagy makes it a crucial process in mitigating hepatocyte damage caused by aberrant accumulation of dysfunctional organelles, for which no other pathway can compensate. This review aims to summarize the types, functions, and dynamics of selective autophagy that are of particular importance in the initiation and progression of NAFLD. And on this basis, the review outlines the therapeutic strategies against NAFLD, in particular the medications and potential natural products that can modulate selective autophagy in the pathogenesis of this disease. The critical roles of lipophagy and mitophagy in the pathogenesis of NAFLD are well established, while reticulophagy and pexophagy are still being identified in this disease due to the insufficient understanding of their molecular details. As gradual blockage of autophagic flux reveals the complexity of NAFLD, studies unraveling the underlying mechanisms have made it possible to successfully treat NAFLD with multiple pharmacological compounds that target associated pathways. Overall, it is convinced that the continued research into selective autophagy occurring in NAFLD will further enhance the understanding of the pathogenesis and uncover novel therapeutic targets.

28 February 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
TXTian-Ji Xia
Tian-Ji Xia
SJSu-Wei Jin
Su-Wei Jin
YLYong-Guang Liu
Yong-Guang Liu
SZShan-Shan Zhang
Shan-Shan Zhang
ZWZhi Wang
Zhi Wang
QCQi Chang
Qi Chang

20 June 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
TXTian-Ji Xia
Tian-Ji Xia
ZWZhi Wang
Zhi Wang
SJSu-Wei Jin
Su-Wei Jin
XLXinmin Liu
Xinmin Liu
YLYong-Guang Liu
Yong-Guang Liu
QCQi Chang
Qi Chang
Stress may trigger sleep disorders and are also risk factors for depression. The study explored the melatonin-related mechanisms of stress-associated sleep disorders on a mouse model of chronic stress by exploring the alteration in sleep architecture, melatonin, and related small molecule levels, transcription and expression of melatonin-related genes as well as proteins. Mice undergoing chronic restraint stress modeling for 28 days showed body weight loss and reduced locomotor activity. Sleep fragmentation, circadian rhythm disorders, and insomnia exhibited in CRS-treated mice formed sleep disorders. Tryptophan and 5-hydroxytryptamine levels were increased in the hypothalamus, while melatonin level was decreased. The transcription and expression of melatonin receptors were reduced, and circadian rhythm related genes were altered. Expression of downstream effectors to melatonin receptors was also affected. These results identified sleep disorders in a mice model of chronic stress. The alteration of melatonin-related pathways was shown to trigger sleep disorders.

29 August 2021 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MYMingzhu Yan
Mingzhu Yan
CZChong Zhao
Chong Zhao
SLShangyun Lu
Shangyun Lu
JCJinling Cui
Jinling Cui
ZSZhenou Sun
Zhenou Sun
HHHongbo Hu
Hongbo Hu